Meiji Holdings Co Ltd of Japan acquired Medreich for 290 million dollar

Jun 12, 2014 14:26 IST

Japan’s Meiji Holdings Ltd on 11 June 2014 acquired Bangalore-based pharmaceutical firm Medreich for 290 million US dollar. Meiji in its filing to the Tokyo Stock Exchange informed that the acquisition was made through the operating subsidiary, Meiji Seika Pharma Co. Ltd.

With this acquisition, Medreich will be a fully-owned subsidiary of Meiji Seika Pharma and the name of the entity will remain unchanged.

The acquisition of Medreich was done as a part of Meiji’s long-term management policy, Meiji Group 2020 Vision. As per the Vision 2020, Meiji Seika Pharma seeks to become a major Specialty and Generic Pharmaceutical Company internationally with particular emphasis on Asia and emerging economies.


About Medreich
Medreich is a fully integrated pharmaceutical company involved in the manufacturing and marketing range of pharmaceutical preparations in various dosages. It caters to diverse Therapeutic categories, across various geographies. It does contract manufacturing of pharmaceutical formulations (CMO) and contract development and manufacturing (CDMO). It also sells generic pharma products to Europe, Asia and Africa.

Medreich had a client base across 54 companies and is involved in manufacturing of formulations for multinationals like GSK, Pfizer, Sanofi Aventis, Wyeth, Adcock Ingram, Mylan, Actavis and many other customers.

Is this article important for exams ? Yes13 People Agreed

DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.

Latest Videos

Register to get FREE updates

    All Fields Mandatory
  • (Ex:9123456789)
  • Please Select Your Interest
  • Please specify

  • ajax-loader
  • A verifcation code has been sent to
    your mobile number

    Please enter the verification code below

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK